TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36631687

Group type: EXPERIMENTAL
Intervention: Levosimendan (LVSMD) infusion at 0.2 µg/kg/min over 24 hours
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Levosimendan (LVSMD) infusion over 48 hours instead of 24 hours
Number of subjects: 27
Study: 36631720

Group type: EXPERIMENTAL
Intervention: Insulin icodec (5.6 U/kg) administered subcutaneously in the thigh
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Insulin icodec (5.6 U/kg) administered subcutaneously in the abdomen
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Insulin icodec (5.6 U/kg) administered subcutaneously in the upper arm
Number of subjects: 25
Study: 36631725

Group type: EXPERIMENTAL
Intervention: T-DM1 + P
Number of subjects: 444

Group type: COMPARATOR
Intervention: TCH + P
Number of subjects: 444
Study: 36631767

Group type: EXPERIMENTAL
Intervention: Trained NCMs (intervention)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untrained NCMs (control)
Number of subjects: 30
Study: 36631812

Group type: EXPERIMENTAL
Intervention: HER2-targeted peptide probe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPECT/CT imaging
Number of subjects: 0
Study: 36631822

Group type: EXPERIMENTAL
Intervention: Group A: Phallopexy (anchoring the penile skin dermis to Buck's fascia at the penile base at 3 and 9 o'clock points using PDS 5/0)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group B: Complete dissection and excision of dartos fascia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group C: Phallopexy after complete dissection and excision of dartos fascia
Number of subjects: 150
Study: 36631821

Group type: EXPERIMENTAL
Intervention: New postpartum haemorrhage care bundle (E-MOTIVE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Proposed interventions (Education, Training, Modelling, Enablement, Persuasion, Environmental Restructuring)
Number of subjects: 45
Study: 36631831

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Volatile agent
Number of subjects: 1804
Study: 36631859

Group type: EXPERIMENTAL
Intervention: Intelligent Decision Support System using two-dimensional video files of cardiac sweeps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard first-trimester fetal echocardiography (FE)
Number of subjects: 0
Study: 36631869

Group type: EXPERIMENTAL
Intervention: Communities for Healthy Living (CHL) intervention during intervention periods
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Parents who enrolled in PConnect
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Control periods
Number of subjects: 1274
Study: 36631895

Group type: EXPERIMENTAL
Intervention: Light breakfast (14 g protein, 2218 kJ)
Number of subjects: 63
Study: 36632042

Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster
Number of subjects: 401

Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: MenACYW-TT and MPSV4
Number of subjects: 401
Study: 36632126

Group type: EXPERIMENTAL
Intervention: probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: blinded pCLE reinterpretation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: pCLE
Number of subjects: 43
Study: 36632180

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 36632603

Group type: EXPERIMENTAL
Intervention: Baseline attention
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Executive control and working memory
Number of subjects: 107
Study: 36632738

Group type: EXPERIMENTAL
Intervention: Venetoclax and rituximab (VenR) combination treatment
Number of subjects: 75
Study: 36632758

Group type: EXPERIMENTAL
Intervention: MIP (metamizole, ibuprofen, paracetamol)
Number of subjects: 110

Group type: COMPARATOR
Intervention: i.p. (ibuprofen and paracetamol)
Number of subjects: 110
Study: 36632763

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study: 36632831

Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia (VT) and ventricular fibrillation (VF) reported as adverse events, incidence rate 0.3 per 100 person-years.
Number of subjects: 13609

Group type: EXPERIMENTAL
Intervention: Occurrence of VT/VF
Number of subjects: 13609

Group type: EXPERIMENTAL
Intervention: Patients with HFmrEF
Number of subjects: 13609
Study: 36632983

Group type: EXPERIMENTAL
Intervention: Teriflunomide (14 mg adult equivalent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36633115

Group type: EXPERIMENTAL
Intervention: Combined PSP/IPP-block before surgery
Number of subjects: 185

Group type: COMPARATOR
Intervention: Long-acting opioids (intravenous morphine 30 min before emergence from anaesthesia)
Number of subjects: 185
Study: 36633418

Group type: EXPERIMENTAL
Intervention: Operatively managed patients with ASH
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Patients with SSI
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Patients with Bluebelle scores
Number of subjects: 218
Study: 36633470

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 352
Study: 36633505

Group type: EXPERIMENTAL
Intervention: ADO09 (pramlintide/insulin A21G)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 44
Study: 36633570

Group type: EXPERIMENTAL
Intervention: 9.6 mg/dose carbetocin
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 3.2 mg/dose carbetocin
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 36633650

Group type: EXPERIMENTAL
Intervention: Upfront surgery
Number of subjects: 119

Group type: COMPARATOR
Intervention: Active surveillance (AS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Biopsy done outside of the center
Number of subjects: 119
Study: 36633657

Group type: COMPARATOR
Intervention: LSHD group (n=42)
Number of subjects: 190
Study: 36633816

Group type: EXPERIMENTAL
Intervention: Vericiguat 10 mg once daily (up-titrated from 2.5 mg to 5 mg to 10 mg at 14-day intervals)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (single dose on day 8 or day 50)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 36633838

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg twice daily for 10 days)
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 1288
Study: 36633844

Group type: EXPERIMENTAL
Intervention: ML recommender
Number of subjects: 1487

Group type: COMPARATOR
Intervention: Standard messaging
Number of subjects: 1487

Group type: EXPERIMENTAL
Intervention: Viral tool kit
Number of subjects: 1487

Group type: COMPARATOR
Intervention: No viral tool kit
Number of subjects: 1487
Study: 36633848

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 159

Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cohort 1 (before COVID-19)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Cohort 2 (during COVID-19)
Number of subjects: 159
Study: 36633868

Group type: EXPERIMENTAL
Intervention: Behavioral nudges to clinicians including weekly emails comparing SIC rates, weekly lists of high-risk patients, and opt-out text messages to prompt SICs before encounters.
Number of subjects: 20506

Group type: EXPERIMENTAL
Intervention: Behavioral nudges to clinicians
Number of subjects: 20506

Group type: COMPARATOR
Intervention: Control group (no behavioral nudges)
Number of subjects: 20506
Study: 36633877

Group type: EXPERIMENTAL
Intervention: MRI guidance
Number of subjects: 156

Group type: COMPARATOR
Intervention: CT guidance
Number of subjects: 156
Study: 36633893

Group type: EXPERIMENTAL
Intervention: Real-time mobile intervention to reduce sedentary behavior (SB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Monitoring-only control condition
Number of subjects: 26
Study: 36633982

Group type: EXPERIMENTAL
Intervention: Combined go/no-go and continuous performance task (GNG/CPT)
Number of subjects: 452
Study: 36634022

Group type: EXPERIMENTAL
Intervention: SB-ED intervention
Number of subjects: 690
Study: 36634037

Group type: EXPERIMENTAL
Intervention: Evidence-based HIV risk reduction intervention
Number of subjects: 20
Study: 36634369

Group type: EXPERIMENTAL
Intervention: Coronary Endothelial Function (CEF) assessed by noninvasive MRI measures during isometric handgrip exercise
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Coronary Endothelial Function (CEF) at baseline
Number of subjects: 82

Group type: COMPARATOR
Intervention: Coronary Endothelial Function (CEF) after 8 weeks in the placebo group (N = 40)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Systemic Endothelial Function (SEF) at baseline or 8 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Coronary Endothelial Function (CEF) at 8 weeks
Number of subjects: 82
Study: 36634389

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 36634453

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 20
Study: 36634636

Group type: EXPERIMENTAL
Intervention: Prehabilitation program (15 sessions)
Number of subjects: 30
Study: 36634692

Group type: EXPERIMENTAL
Intervention: RSV resurgence in summer and autumn 2021
Number of subjects: 310423
Study: 36634920

Group type: EXPERIMENTAL
Intervention: Pixatimod 25 mg plus nivolumab 240 mg
Number of subjects: 58
Study: 36635100

Group type: EXPERIMENTAL
Intervention: Occupational asbestos exposure
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Ever smoking
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Interaction of ever smoking with occupational asbestos exposure
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Stratification for genotype
Number of subjects: 494
Study: 36635259

Group type: EXPERIMENTAL
Intervention: ATV014
Number of subjects: 0
Study: 36635304

Group type: EXPERIMENTAL
Intervention: β2-agonist treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36635381

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 68
Study: 36635466

Group type: EXPERIMENTAL
Intervention: Large-pore polypropylene mesh (Ultrapro)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Small-pore mesh
Number of subjects: 181
Study: 36635514

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 47
Study: 36635607

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (ICA)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (ECA)
Number of subjects: 975
Study: 36635633

Group type: EXPERIMENTAL
Intervention: Patients with chronic decompensated heart failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in dyspnea, MLHFQ, and TFI scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consultation frequency
Number of subjects: 0
Study: 36635660

Group type: EXPERIMENTAL
Intervention: Durable Wall Lining (DWL) with non-pyrethroid insecticides
Number of subjects: 100

Group type: COMPARATOR
Intervention: LLIN (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DWL
Number of subjects: 100
Study: 36635679

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS) followed by video game-based training (VBT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham stimulation followed by video game-based training (VBT)
Number of subjects: 9
Study: 36635680

Group type: EXPERIMENTAL
Intervention: Self-reported overweight and obesity at age 20
Number of subjects: 57902

Group type: EXPERIMENTAL
Intervention: Weight gain from age 20
Number of subjects: 57902
Study: 36635690

Group type: EXPERIMENTAL
Intervention: Plasma GAS6 levels
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Baseline plasma GAS6 levels
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: GAS6 measurement
Number of subjects: 1039
Study: 36635717

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chest computed tomography (CT) scan
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peak V'O
Number of subjects: 60
Study: 36635741

Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT-I intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Internet sleep education control
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT-Pain intervention
Number of subjects: 180
Study: 36635747

Group type: EXPERIMENTAL
Intervention: ERVIN.2 supported care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-utility analysis using EQ-5D-3L
Number of subjects: 0
Study: 36635764

Group type: EXPERIMENTAL
Intervention: Root canal treatment in a single visit (RCT-SV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Root canal treatment in two visits with intracanal dressing (RCT-TVWD)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Root canal treatment in two visits without intracanal dressing (RCT-TVWOD)
Number of subjects: 150

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study: 36635767

Group type: EXPERIMENTAL
Intervention: Palbociclib and letrozole
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Palbociclib and fulvestrant
Number of subjects: 221
Study: 36635775

Group type: EXPERIMENTAL
Intervention: Meditation intervention (4-week duration, 4 facilitator-led group sessions, one per week)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Expressive writing control group
Number of subjects: 71
Study: 36636059

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 36636112

Group type: EXPERIMENTAL
Intervention: Intervention (preterm birth prevention education, employment navigation toolkit, encouragement text messages)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 30
Study: 36636296

Group type: EXPERIMENTAL
Intervention: Single, moderate dose of psilocybin (0.215 mg/kg body weight)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 36636317

Group type: EXPERIMENTAL
Intervention: Postpartum patient navigation program
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Navigator training recommendations
Number of subjects: 28
Study: 36636739

Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg, subcutaneous)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 36636751

Group type: EXPERIMENTAL
Intervention: Sensorized exercise using FitMi (computer game with 2 puck-like sensors, 3 hours/week for 3 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional therapy using a paper book of exercises (3 hours/week for 3 weeks)
Number of subjects: 27
Study: 36636767

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AEX) for 20 minutes at moderately-high intensity
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rest (non-exercise group)
Number of subjects: 30
Study: 36636993

Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emicizumab administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laboratory monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylaxis before minor surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major surgeries with emicizumab
Number of subjects: 0
Study: 36637054

Group type: COMPARATOR
Intervention: HbF inducers (HQK-1001, Radix Astragali, CNP)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Hydroxyurea versus resveratrol
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Hydroxyurea 20 mg/kg/day versus 10 mg/kg/day
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus resveratrol versus resveratrol or hydroxyurea alone
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus l-carnitine versus hydroxyurea alone
Number of subjects: 291
Study: 36637138

Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Biomedical education
Number of subjects: 184
Study: 36637153

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg, 10 mg, 5 mg, 2.5 mg, 1 mg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tamoxifen (low-dose: 2.5-5 mg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tamoxifen (high-dose: 10-20 mg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 36637209

Group type: EXPERIMENTAL
Intervention: Prednisolone (∼0.3 mg/kg) for 6 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo/control for 6 months
Number of subjects: 35
Study: 36637540

Group type: EXPERIMENTAL
Intervention: Drip feeding (3-h continuous)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intermittent feeding (bolus in 10 min)
Number of subjects: 51
Study: 36637713

Group type: COMPARATOR
Intervention: LuCa course only
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: LuCa + HD courses
Number of subjects: 91
Study: 36637808

Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uterine Artery Embolization
Number of subjects: 0
Study: 36637994

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean HbA1c
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HbA1c SD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-varying HbA1c
Number of subjects: 0
Study: 36638072

Group type: EXPERIMENTAL
Intervention: Total artificial sweetener intake
Number of subjects: 103388

Group type: EXPERIMENTAL
Intervention: Aspartame intake
Number of subjects: 103388

Group type: EXPERIMENTAL
Intervention: Acesulfame potassium intake
Number of subjects: 103388

Group type: EXPERIMENTAL
Intervention: Sucralose intake
Number of subjects: 103388
Study: 36638112

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 36638206

Group type: EXPERIMENTAL
Intervention: Self-managed, music-guided exercise intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 26
Study: 36638337

Group type: EXPERIMENTAL
Intervention: D+ RBC transfusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Retrospective study of serologic D- pregnant women
Number of subjects: 42

Group type: COMPARATOR
Intervention: Retrospective examination of serologic D- pregnant women with alloanti-D
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Analysis of RHD transcripts from Asian-type DEL erythroblasts
Number of subjects: 42
Study: 36638598

Group type: EXPERIMENTAL
Intervention: Active iTBS for 4 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham iTBS for 4 weeks
Number of subjects: 49
Study: 36638745

Group type: EXPERIMENTAL
Intervention: Medical cannabis card (MCC)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 181
Study: 36638819

Group type: EXPERIMENTAL
Intervention: SIIPL-PCV
Number of subjects: 660

Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 660

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 660

Group type: COMPARATOR
Intervention: SIIPL-PCV vs PHiD-CV
Number of subjects: 660

Group type: COMPARATOR
Intervention: SIIPL-PCV vs PCV13
Number of subjects: 660
Study: 36638837

Group type: EXPERIMENTAL
Intervention: CSCC_ASC injections
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 81
Study: 36639035

Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT-guided intensification of radiation therapy (PSMAgRT)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 253
Study: 36639130

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study: 36639200

Group type: EXPERIMENTAL
Intervention: FGFR3 inhibitor
Number of subjects: 0
Study: 36639210

Group type: EXPERIMENTAL
Intervention: Video laryngoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 0
Study: 36639237

Group type: EXPERIMENTAL
Intervention: BrainGate Neural Interface system
Number of subjects: 14
Study: 36639249

Group type: EXPERIMENTAL
Intervention: diazoxide choline extended-release tablet (DCCR)
Number of subjects: 127

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 127
Study: 36639328

Group type: EXPERIMENTAL
Intervention: Ephedrine 1.2 mg kg
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Ephedrine doses much higher than those used in adults (∼10-fold)
Number of subjects: 119
Study: 36639329

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250mg b.i.d for 5 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 28
Study: 36639540

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of rectus femoris cross-sectional area (RFcsa) on days 1 and 7 of ICU stay
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 28-day mortality rate
Number of subjects: 104
Study: 36639565

Group type: EXPERIMENTAL
Intervention: Cognitive stress protocol (20-min alternating relaxation and cognitive stress)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy female controls
Number of subjects: 82
Study: 36639624

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation after surgery
Number of subjects: 1771

Group type: COMPARATOR
Intervention: Discharge directly home
Number of subjects: 1771
Study: 36639636

Group type: EXPERIMENTAL
Intervention: Grades 3-4 hyperbilirubinemia during induction/consolidation treatment
Number of subjects: 1547

Group type: COMPARATOR
Intervention: Grades 1-2 hyperbilirubinemia during induction/consolidation treatment
Number of subjects: 1547

Group type: COMPARATOR
Intervention: Grade 0 hyperbilirubinemia during induction/consolidation treatment
Number of subjects: 1547
Study: 36639798

Group type: EXPERIMENTAL
Intervention: early-PN
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: late-PN
Number of subjects: 818

Group type: COMPARATOR
Intervention: healthy children
Number of subjects: 818